featured
QoL and Productivity Improvement With Fremanezumab After Poor Response to Other Migraine Prophylactics
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Headache
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study
Headache 2021 Aug 10;[EPub Ahead of Print], ELH Spierings, X Ning, V Ramirez Campos, JM Cohen, S Barash, DC BuseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.